186 related articles for article (PubMed ID: 29078982)
1. Topical Reformulation of Valsartan for Treatment of Chronic Diabetic Wounds.
Abadir P; Hosseini S; Faghih M; Ansari A; Lay F; Smith B; Beselman A; Vuong D; Berger A; Tian J; Rini D; Keenahan K; Budman J; Inagami T; Fedarko N; Marti G; Harmon J; Walston J
J Invest Dermatol; 2018 Feb; 138(2):434-443. PubMed ID: 29078982
[TBL] [Abstract][Full Text] [Related]
2. [The experimental study of captopril and valsartan on the preventing and treatment of diabetic retinopathy in diabetic mice].
Xie XW; Zhao P
Zhonghua Yan Ke Za Zhi; 2004 Nov; 40(11):770-3. PubMed ID: 15634486
[TBL] [Abstract][Full Text] [Related]
3. Ameliorative effect of Captopril and Valsartan on an animal model of diabetic cardiomyopathy.
Zhang CH; Lu J; Yu XJ; Sun L; Zang WJ
Biol Pharm Bull; 2008 Nov; 31(11):2045-9. PubMed ID: 18981571
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin type 1a receptor-deficient mice develop diabetes-induced cardiac dysfunction, which is prevented by renin-angiotensin system inhibitors.
Yong QC; Thomas CM; Seqqat R; Chandel N; Baker KM; Kumar R
Cardiovasc Diabetol; 2013 Nov; 12():169. PubMed ID: 24215514
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular hypertrophy in diabetic spontaneously hypertensive rats: optimizing blockade of the renin-angiotensin system.
Lassila M; Davis BJ; Allen TJ; Burrell LM; Cooper ME; Cao Z
Clin Sci (Lond); 2003 Apr; 104(4):341-7. PubMed ID: 12653675
[TBL] [Abstract][Full Text] [Related]
7. Adenosine Diphosphate Improves Wound Healing in Diabetic Mice Through P2Y
Borges PA; Waclawiak I; Georgii JL; Fraga-Junior VDS; Barros JF; Lemos FS; Russo-Abrahão T; Saraiva EM; Takiya CM; Coutinho-Silva R; Penido C; Mermelstein C; Meyer-Fernandes JR; Canto FB; Neves JS; Melo PA; Canetti C; Benjamim CF
Front Immunol; 2021; 12():651740. PubMed ID: 33828561
[TBL] [Abstract][Full Text] [Related]
8. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
McMurray J; Solomon S; Pieper K; Reed S; Rouleau J; Velazquez E; White H; Howlett J; Swedberg K; Maggioni A; Køber L; Van de Werf F; Califf R; Pfeffer M
J Am Coll Cardiol; 2006 Feb; 47(4):726-33. PubMed ID: 16487836
[TBL] [Abstract][Full Text] [Related]
9. Effects of valsartan, an angiotensin II receptor blocker, on coronary atherosclerosis in patients with acute myocardial infarction who receive an angiotensin-converting enzyme inhibitor.
Yano H; Hibi K; Nozawa N; Ozaki H; Kusama I; Ebina T; Kosuge M; Tsukahara K; Okuda J; Morita S; Umemura S; Kimura K
Circ J; 2012; 76(6):1442-51. PubMed ID: 22473458
[TBL] [Abstract][Full Text] [Related]
10. Combined effect of substance P and curcumin on cutaneous wound healing in diabetic rats.
Kant V; Kumar D; Prasad R; Gopal A; Pathak NN; Kumar P; Tandan SK
J Surg Res; 2017 May; 212():130-145. PubMed ID: 28550899
[TBL] [Abstract][Full Text] [Related]
11. Pien Tze Huang accelerated wound healing by inhibition of abnormal fibroblast apoptosis in Streptozotocin induced diabetic mice.
Yan Y; Liu X; Zhuang Y; Zhai Y; Yang X; Yang Y; Wang S; Hong F; Chen J
J Ethnopharmacol; 2020 Oct; 261():113203. PubMed ID: 32721552
[TBL] [Abstract][Full Text] [Related]
12. The kinin B1 receptor contributes to the cardioprotective effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in mice.
Xu J; Carretero OA; Shesely EG; Rhaleb NE; Yang JJ; Bader M; Yang XP
Exp Physiol; 2009 Mar; 94(3):322-9. PubMed ID: 19060116
[TBL] [Abstract][Full Text] [Related]
13. Effects of plasma fibronectin on the healing of full-thickness skin wounds in streptozotocin-induced diabetic rats.
Qiu Z; Kwon AH; Kamiyama Y
J Surg Res; 2007 Mar; 138(1):64-70. PubMed ID: 17161431
[TBL] [Abstract][Full Text] [Related]
14. Preventing microalbuminuria with benazepril, valsartan, and benazepril-valsartan combination therapy in diabetic patients with high-normal albuminuria: A prospective, randomized, open-label, blinded endpoint (PROBE) study.
Ruggenenti P; Cortinovis M; Parvanova A; Trillini M; Iliev IP; Bossi AC; Belviso A; Aparicio MC; Trevisan R; Rota S; Perna A; Peracchi T; Rubis N; Martinetti D; Prandini S; Gaspari F; Carrara F; De Cosmo S; Tonolo G; Mangili R; Remuzzi G;
PLoS Med; 2021 Jul; 18(7):e1003691. PubMed ID: 34260595
[TBL] [Abstract][Full Text] [Related]
15. Mechanism for blockade of angiotensin subtype 1 receptors to lower plasma glucose in streptozotocin-induced diabetic rats.
Chan P; Liu IM; Tzeng TF; Yang TL; Cheng JT
Diabetes Obes Metab; 2007 Jan; 9(1):39-49. PubMed ID: 17199717
[TBL] [Abstract][Full Text] [Related]
16. Wound Healing Effect of Kaempferol in Diabetic and Nondiabetic Rats.
Özay Y; Güzel S; Yumrutaş Ö; Pehlivanoğlu B; Erdoğdu İH; Yildirim Z; Türk BA; Darcan S
J Surg Res; 2019 Jan; 233():284-296. PubMed ID: 30502261
[TBL] [Abstract][Full Text] [Related]
17. FPS-ZM1 and valsartan combination protects better against glomerular filtration barrier damage in streptozotocin-induced diabetic rats.
Sanajou D; Ghorbani Haghjo A; Argani H; Roshangar L; Ahmad SNS; Jigheh ZA; Aslani S; Panah F; Rashedi J; Mesgari Abbasi M
J Physiol Biochem; 2018 Aug; 74(3):467-478. PubMed ID: 29948786
[TBL] [Abstract][Full Text] [Related]
18. Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial.
Seferovic JP; Claggett B; Seidelmann SB; Seely EW; Packer M; Zile MR; Rouleau JL; Swedberg K; Lefkowitz M; Shi VC; Desai AS; McMurray JJV; Solomon SD
Lancet Diabetes Endocrinol; 2017 May; 5(5):333-340. PubMed ID: 28330649
[TBL] [Abstract][Full Text] [Related]
19. VALIANT (VALsartan In Acute myocardial iNfarcTion) trial.
Maggioni AP; Fabbri G
Expert Opin Pharmacother; 2005 Mar; 6(3):507-12. PubMed ID: 15794740
[TBL] [Abstract][Full Text] [Related]
20. Effects of add-on fluvastatin therapy in patients with chronic proteinuric nephropathy on dual renin-angiotensin system blockade: the ESPLANADE trial.
Ruggenenti P; Perna A; Tonelli M; Loriga G; Motterlini N; Rubis N; Ledda F; Rota S; Satta A; Granata A; Battaglia G; Cambareri F; David S; Gaspari F; Stucchi N; Carminati S; Ene-Iordache B; Cravedi P; Remuzzi G;
Clin J Am Soc Nephrol; 2010 Nov; 5(11):1928-38. PubMed ID: 20671225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
